Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts
FC Arnett, M Cho, S Chatterjee… - … : Official Journal of …, 2001 - Wiley Online Library
FC Arnett, M Cho, S Chatterjee, MB Aguilar, JD Reveille, MD Mayes
Arthritis & Rheumatism: Official Journal of the American College …, 2001•Wiley Online LibraryObjective To determine the frequency with which scleroderma (systemic sclerosis; SSc)
recurs in families and the familial relative risk (λ) in the US. Methods Family histories of SSc
were prospectively surveyed in 3 large US cohorts of SSc patients, 2 in Texas and 1 in
Michigan. Diagnoses of familial SSc were verified by rheumatologist evaluation and/or
review of medical records. Familial relative risks for first‐degree relatives (λ1) and siblings
(λs) were calculated using actual reported counts of first‐degree relatives in 2 cohorts and …
recurs in families and the familial relative risk (λ) in the US. Methods Family histories of SSc
were prospectively surveyed in 3 large US cohorts of SSc patients, 2 in Texas and 1 in
Michigan. Diagnoses of familial SSc were verified by rheumatologist evaluation and/or
review of medical records. Familial relative risks for first‐degree relatives (λ1) and siblings
(λs) were calculated using actual reported counts of first‐degree relatives in 2 cohorts and …
Objective
To determine the frequency with which scleroderma (systemic sclerosis; SSc) recurs in families and the familial relative risk (λ) in the US.
Methods
Family histories of SSc were prospectively surveyed in 3 large US cohorts of SSc patients, 2 in Texas and 1 in Michigan. Diagnoses of familial SSc were verified by rheumatologist evaluation and/or review of medical records. Familial relative risks for first‐degree relatives (λ1) and siblings (λs) were calculated using actual reported counts of first‐degree relatives in 2 cohorts and recent estimates of SSc prevalence in the US.
Results
Compared with the estimated prevalence of SSc in the US (2.6 cases/10,000 population [0.026%]), the disease occurred in 1 or more first‐degree relatives in 1.5–1.7% of SSc families in the 3 cohorts (or 11 of 703 families [1.6%]), a significant increase. Familial relative risks in first‐degree relatives in the 3 cohorts ranged from 10 to 16 (13 combined), and in siblings they ranged from 10 to 27 (15 combined).
Conclusion
SSc occurs significantly more frequently in families with scleroderma (1.6%) than in the general population (0.026%). A positive family history of SSc is the strongest risk factor yet identified for SSc; however, the absolute risk for each family member remains quite low (<1%).
Wiley Online Library